Bronchiectasis Alternative Therapy

Individuals With Bronchiectasis May Benefit From an Alternative Therapy – Cellular Treatment

Cellular therapy is a breakthrough alternative for many individuals with bronchiectasis. This innovative treatment is available at the Lung Institute, the only cellular therapy center in the world that focuses exclusively on treating chronic obstructive lung conditions. While cellular therapy is not curative, it can potentially halt the progression of bronchiectasis, improve lung function and enhance quality of life.

This means that cells can potentially serve as a healing mechanism and replicate healthy lung tissue that has been lost through damage, such as the scarring that occurs as a result of bronchiectasis.

At the Lung Institute, we offer blood-based cellular therapy as an alternative treatment for bronchiectasis. In accordance with our treatment guidelines, these minimally invasive procedures are performed on an outpatient basis over the course of two days. In general, cellular therapy involves three main steps:

  • Harvesting cells from a patient’s blood
  • Isolating the cells in our in-house lab
  • Reintroducing the concentrated cells into the patient’s bloodstream via intravenous infusions

The Lung Institute upholds the highest level of medical standards and quality with a full compliance team overseeing all operations. Our clean, bright and modern facilities are staffed by a dedicated team of compassionate professionals who work hard to ensure an exceptional, concierge-like patient experience.

If you’d like to learn more about cellular therapy as an alternative treatment for bronchiectasis, contact the Lung Institute at (800) 729-3065 to discuss your options.

* Every patient is given a Patient Satisfaction Survey shortly after treatment. Responses to the 11-question survey are aggregated to determine patient satisfaction with the delivery of treatment.

^ Quality of Life Survey data measured the patient’s self-assessed quality of life and measurable quality of improvement at three months of COPD patients.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.

Each patient is different. Results may vary.